华安基金：春节期间科技热点频出，创业板50指数聚焦四大新质生产力赛道

Market Overview - The A-share market showed an overall upward trend before the holiday, with the CSI 300 rising by 0.36%, the CSI 1000 by 1.90%, the ChiNext 50 by 1.10%, and the Sci-Tech 50 by 3.37% [1][8] - Global stock markets mostly rose during the Spring Festival break, indicating a favorable global risk appetite [1][8] - The liquidity outlook remains stable despite uncertainties in the Federal Reserve's interest rate path, and the offshore RMB exchange rate remained steady during the holiday [1][8] Industry Trends - Technology hotspots, including robotics and domestic large models, continue to gain traction [1][8] - The upcoming Two Sessions are expected to reinforce market stability expectations, while confirmation of Trump's planned visit to China in late March may help stabilize external environment expectations [1][8] - The ChiNext serves as a direct financing platform for innovative enterprises focusing on "three innovations (innovation, creation, creativity)" and "four new (new technologies, new industries, new business formats, new models)" [1][8] ChiNext 50 Index Insights - The ChiNext 50 Index focuses on four key sectors: information technology, new energy, financial technology, and pharmaceuticals, reflecting a pure technology growth attribute [1][8] - The index has a significant concentration in the information technology sector, comprising 54% of its weight, with high-weight companies in optical modules and AI applications benefiting from global AI capital expenditure expansion [3][10] - The performance of the ChiNext 50 ETF (159949) is highlighted, with a current valuation of 42.76 times, placing it in the 45.28% percentile over the past decade [3][10] Sector-Specific Developments New Energy and Photovoltaics - February is expected to be the low point for annual production, with a projected increase in lithium battery production starting in March, returning to a high point not seen since 2025 [11] - Tesla's photovoltaic planning has surged from an initial 10GW to 50GW, with a requirement for delivery by Q3 this year, significantly enhancing order certainty [11] Pharmaceuticals and Biotechnology - Recent overseas licensing agreements by local companies in innovative drugs validate the increasing global competitiveness of Chinese innovation drugs and the acceleration of internationalization [11] - The pharmaceutical sector is expected to enter a catalyst-rich period post-holiday, with industry conferences and earnings reports on the horizon [11]